HIV-associated lymphoma · 15 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
R-CHOP Variant #23 | — | R 59 865 | 21d | ~14.4 mo | ~55.7 mo | ~21 | ~R 1 257 163 PFS proxy · indirect | 11 |
GMALL-R N/A - protocol Partial | — | R 47 452 | 5d | — | — | — | — | — |
R-CDOP Variant #01 | — | R 25 751 | 21d | — | — | — | — | — |
SC-EPOCH-RR Variant #01 | — | R 25 093 | 21d | — | — | — | — | — |
R-CODOX-M/R-IVAC N/A - intrathecal component | — | R 12 115 | — | — | — | — | — | 1 |
R-CODOX-M N/A - intrathecal component | — | R 3 176 | 28d | — | — | — | — | — |
Stanford V Variant #05 Partial | — | R 2 608 | 28d | — | — | — | — | 1 |
CODOX-M/IVAC N/A - intrathecal component | — | R 2 560 | — | — | — | — | — | — |
EPOCH, dose-escalated Variant #01 | — | R 1 367 | 21d | — | — | — | — | — |
R-EPOCH, dose-escalated Variant #01 | — | R 1 367 | 21d | — | — | — | — | — |
dmCODOX-M/IVAC - Modified Magrath N/A - intrathecal component | — | R 1 240 | — | — | — | — | — | — |
CHOP Variant #13 | — | R 859 | 21d | — | — | — | — | 1 |
m-BACOD Variant #01 | — | R 837 | 21d | — | 7.6 mo | — | — | 2 |
CODOX-M N/A - intrathecal component | — | R 572 | — | — | — | — | — | — |
dmCODOX-M - Modified Magrath N/A - intrathecal component | — | R 211 | — | — | — | — | — | — |
15 of 15 regimens shown